UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 82 filers reported holding UROGEN PHARMA LTD in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $94,000 | +9.3% | 4,829 | +1.5% | 0.00% | – |
| Q4 2020 | $86,000 | -61.3% | 4,758 | -58.7% | 0.00% | – |
| Q3 2020 | $222,000 | -24.5% | 11,512 | +2.1% | 0.00% | -100.0% |
| Q2 2020 | $294,000 | +182.7% | 11,274 | +93.9% | 0.00% | 0.0% |
| Q1 2020 | $104,000 | -44.4% | 5,814 | +3.5% | 0.00% | 0.0% |
| Q4 2019 | $187,000 | +34.5% | 5,616 | -3.7% | 0.00% | 0.0% |
| Q3 2019 | $139,000 | -33.5% | 5,832 | +0.3% | 0.00% | 0.0% |
| Q2 2019 | $209,000 | +26.7% | 5,813 | +30.1% | 0.00% | 0.0% |
| Q1 2019 | $165,000 | -12.2% | 4,468 | +2.4% | 0.00% | 0.0% |
| Q4 2018 | $188,000 | +16.0% | 4,364 | +27.6% | 0.00% | 0.0% |
| Q3 2018 | $162,000 | +1.2% | 3,420 | +6.1% | 0.00% | 0.0% |
| Q2 2018 | $160,000 | +6.7% | 3,224 | +6.5% | 0.00% | 0.0% |
| Q1 2018 | $150,000 | +42.9% | 3,026 | +7.2% | 0.00% | 0.0% |
| Q4 2017 | $105,000 | – | 2,824 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |